NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

40.2M

Vuru Grade

30.66/100

Current Price

$0.79
+0.012 (+1.54%)

Stability Price

$0.62
Overvalued by 21.13%

Company Metrics

  • 0 P/E
  • 19.61 P/S
  • 4.29 P/B
  • -0.335 EPS
  • -2,345.19% Cash ROIC
  • 3.60 Cash Ratio
  • 0 / 0% Dividend
  • 296,831.00 Avg. Vol.
  • 38.18M Shares
  • 40.2M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay off big after trial fails (NBY)
Seeking Alpha (registration) - Aug 20, 2014
The global study enrolled patients with adenoviral conjunctivitis in the U.S., India, Sri Lanka and Brazil. The endpoints were: measured clearing of bulbar conjunctival injection (red eye); eradication of adenovirus from tear film; spread of infection ...
NovaBay Pharmaceuticals Deploys Direct Sales Force to Market i-Lid Cleanser ...
Yahoo Finance UK - Aug 25, 2014
NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that its i-Lid Cleanser sales force has been deployed in 10 ...
NovaBay Pharmaceuticals Adds Five Top Ophthalmologists to its Ophthalmic ...
Business Wire (press release) - Aug 28, 2014
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that it has added ...
Today's Hot List: NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY), Oi SA ...
eFinance Hub - Aug 21, 2014
NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) announced that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis.
Active Stocks: NovaBay Pharmaceuticals (NYSEMKT:NBY), Novatel Wireless ...
Tech News - Aug 26, 2014
On 20 AUG NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) announced that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis.
Hot Stock List: Canadian Solar Inc. (NASDAQ:CSIQ), NovaBay Pharmaceuticals ...
Crazy Joys - Aug 18, 2014
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infectives, reported July 31 second quarter 2014 financial results and provided a clinical and ...
Traders Stocks Alert: EXACT Sciences Corporation (NASDAQ:EXAS), NovaBay ...
Market News Call - Aug 19, 2014
... investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on EXACT Sciences Corporation (NASDAQ:EXAS), NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), Ampio Pharmaceuticals Inc (NYSEMKT:AMPE).
Stocks in the News - EXACT Sciences Corporation (NASDAQ:EXAS), American ... - Techsonian (press release)
Trader's Recap: OvaScience (NASDAQ:OVAS), NovaBay Pharmaceuticals ...
Crazy Joys - Aug 17, 2014
On 7 AUG OvaScience, Inc. (NASDAQ:OVAS) issued its quarterly earnings data on Thursday. The company reported ($0.42) earnings per share for the quarter, beating the analysts' consensus estimate of ($0.45) by $0.03.
Stocks to Track - NovaBay Pharmaceuticals, Inc. (NBY), Dyax Corp. (DYAX ...
Techsonian (press release) - Aug 25, 2014
Birmingham, West Midlands - (TechSonian) - 25 August 2014 - NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY)released that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with ...
Today's Watch List: Bio-Path Holdings (NASDAQ:BPTH), NovaBay ... - WallStreet Scope
Today's Hot List: NovaBay Pharmaceuticals (NYSEMKT:NBY), IHS (NYSE:IHS ...
Tech News - Aug 20, 2014
On July 31,2014 NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infectives, today reported second quarter 2014 financial results and provided a ...